Diaryl ether derivative inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells.

Papillary thyroid carcinoma contributes to about 80% of the total thyroid cancer cases. BRAFV600E is a frequently occurring mutation in PTCs. Although several BRAF inhibitors are available, many thyroid cancer patients acquire resistance to BRAF inhibitors. Therefore, new targets and drugs need to be identified as therapies. Ferroptosis is a recently discovered type of cell death, and inhibiting glutathione peroxidase 4 (GPX4) using small molecules was found to trigger ferroptosis. But it is unknown whether inhibiting GPX4 renders thyroid cancer cells susceptible to ferroptosis. To identify novel GPX4 inhibitors, we focused on our previously reported cohort of diaryl ether and dibenzoxepine molecules. In this study, we asked whether diaryl ether and dibenzoxepine derivatives trigger ferroptosis in thyroid cancer cells. To answer this question, we screened diaryl ether and dibenzoxepine derivatives in cell-based assays and performed mechanism of action studies. We found that a diaryl ether derivative, 16 decreased thyroid cell proliferation and triggered ferroptosis by inhibiting GPX4 expression levels. Molecular modeling and dynamics simulations showed that 16 binds to the active site of GPX4. Upon deciphering the mode of 16-induced ferroptosis, we found that 16 treatments decrease mitochondrial polarization and reduce mitochondrial respiration similar to a ferroptosis inducer, RSL3. We conclude that the diaryl ether derivative, 16 inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells. Based on our observations, we suggest that 16 can be lead-optimized and developed as a ferroptosis-inducing agent to treat thyroid cancers.

[1]  B. Stockwell,et al.  Small-molecule allosteric inhibitors of GPX4. , 2022, Cell chemical biology.

[2]  K. Sekhar,et al.  Ferroptosis Inducers in Thyroid Cancer , 2022, World Journal of Surgery.

[3]  B. Stockwell,et al.  Characterization of a patient-derived variant of GPX4 for precision therapy , 2021, Nature Chemical Biology.

[4]  N. Jain,et al.  Mutant IDH1 inhibitors activate pSTAT3-Y705 leading to an increase in BCAT1 and YKL-40 levels in mutant IDH1-expressing cells. , 2021, Biochimica et biophysica acta. Molecular cell research.

[5]  N. Jain,et al.  APC/C CDH1 ubiquitinates IDH2 contributing to ROS increase in mitosis. , 2021, Cellular signalling.

[6]  S. Yadav,et al.  N ‐Heterocyclic Carbene (NHC)‐Catalyzed Intramolecular Stetter Reaction to Access Dibenzo‐fused Seven‐membered Heterocycles , 2021 .

[7]  K. Kalia,et al.  Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir , 2021, Scientific Reports.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  B. Stockwell,et al.  Ferroptosis: mechanisms, biology and role in disease , 2021, Nature Reviews Molecular Cell Biology.

[10]  B. Stockwell,et al.  The Chemistry and Biology of Ferroptosis. , 2020, Cell chemical biology.

[11]  P. Clemons,et al.  Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles , 2020, Nature Chemical Biology.

[12]  Marcus Conrad,et al.  The chemical basis of ferroptosis , 2019, Nature Chemical Biology.

[13]  Can Liu,et al.  Mitochondria regulation in ferroptosis. , 2019, European journal of cell biology.

[14]  M. Landriscina,et al.  BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives , 2019, Cancers.

[15]  N. Jain,et al.  Abundance of d‐2‐hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1‐expressing cells , 2019, FEBS letters.

[16]  D. Krysko,et al.  Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion , 2019, Nature Reviews Cancer.

[17]  E. Sokol,et al.  Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations , 2018, Cancer biology & therapy.

[18]  J. Pin,et al.  From the Promiscuous Asenapine to Potent Fluorescent Ligands Acting at a Series of Aminergic G-Protein-Coupled Receptors. , 2018, Journal of medicinal chemistry.

[19]  Xiuping Chen,et al.  Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells , 2018, Scientific Reports.

[20]  N. Jain,et al.  Novel Gomisin B analogues as potential cytotoxic agents: Design, synthesis, biological evaluation and docking studies. , 2017, European journal of medicinal chemistry.

[21]  M. Bhasin,et al.  Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E , 2017, Oncotarget.

[22]  M. Rauh,et al.  Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis , 2017, Oncogenesis.

[23]  Jill P. Mesirov,et al.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.

[24]  H. Sies.  Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress☆ , 2017, Redox biology.

[25]  Pritish Kumar Varadwaj,et al.  Structural insights into conformational stability of both wild-type and mutant EZH2 receptor , 2016, Scientific Reports.

[26]  C. Rudin,et al.  A combinatorial strategy for treating KRAS mutant lung cancer , 2016, Nature.

[27]  M. Hofmann,et al.  Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model , 2016, Oncotarget.

[28]  K. Ulgen,et al.  A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors. , 2016, Journal of molecular graphics & modelling.

[29]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[30]  John A. Tallarico,et al.  Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo , 2014, Nature Cell Biology.

[31]  D. Velmurugan,et al.  Virtual screening and discovery of novel aurora kinase inhibitors. , 2014, Current topics in medicinal chemistry.

[32]  Matthew E. Welsch,et al.  Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.

[33]  N. Jain,et al.  Design and synthesis of resveratrol-based nitrovinylstilbenes as antimitotic agents. , 2011, Journal of medicinal chemistry.

[34]  Veroniki P. Vidali,et al.  Diaryl Ether Formation in the Synthesis of Natural Products , 2011 .

[35]  N. Arora,et al.  Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase , 2010 .

[36]  W. Sherman,et al.  Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. , 2010, Journal of chemical theory and computation.

[37]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[38]  Joel S. Freundlich,et al.  Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives. , 2006, Bioorganic & medicinal chemistry letters.

[39]  Q. Lu,et al.  Synthesis and biological activities of aryl-ether-, biaryl-, and fluorene-aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT-2. , 2005, Bioorganic & medicinal chemistry letters.

[40]  Shinichi Suzuki,et al.  BRAF mutations in papillary carcinomas of the thyroid , 2003, Oncogene.

[41]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[42]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[43]  R. Hilf,et al.  A fluorometric method for determination of oxidized and reduced glutathione in tissues. , 1976, Analytical biochemistry.